1131614-23-7Relevant articles and documents
A robust process for an mGluR5 negative allosteric modulator: Difluoromethylation and sonogashira coupling on large scale
Sperry, Jeffrey B.,Farr, Roger M.,Levent, Mahmut,Ghosh, Mousumi,Hoagland, Steven M.,Varsolona, Richard J.,Sutherland, Karen
, p. 1854 - 1860 (2012)
The development of the potent and selective mGluR5 negative allosteric modulator (NAM) 1 is described. Key features in the process, which has been implemented on a multikilogram scale, include a high-temperature difluoromethylation reaction, a Sonogashira coupling, and careful control of residual Pd and Cu in the final API. Due to the relative nonpolar nature of the intermediates, water-miscible solvents were employed in all four steps to allow for direct crystallizations upon reaction completion. In addition, several crystalline morphologies of the API were discovered, and the isolation of the desired form II will be discussed.
A new route to Roflumilast via copper-catalyzed hydroxylation
Ni, Feng,Li, Jianqi
, p. 3598 - 3602 (2013/02/22)
A new route to Roflumilast, a selective phosphodiesterase type 4 (PDE 4) inhibitor, is described. The synthetic procedure starts from 4-hydroxy-3-iodobenzoic acid to access the key intermediate 3- (cyclopropylmethoxy)-4-(difluoromethoxy)benzoic acid via copper-catalyzed hydroxylation and utilizes amide coupling to accomplish the synthesis of Roflumilast in 80% overall yield. Georg Thieme Verlag KG Stuttgart · New York.
BISARYL ALKYNYLAMIDES AS NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLUR5)
-
Page/Page column 58-59, (2010/11/05)
Disclosed are compounds of Formula (I): pharmaceutical compositions containing compounds of Formula I, and the use of compounds of Formula (I) to treat diseases and disorders including schizophrenia, paranoia, depression, manic-depressive illness and anxiety wherein W1-W5, X1-X4, Y, Z1-Z5, m, n, p, and R1-R6 in Formula (I) are defined in the specification.